AGAP3: A novel BRAF fusion partner in pediatric pancreatic-type acinar cell carcinoma.


Journal

Genes, chromosomes & cancer
ISSN: 1098-2264
Titre abrégé: Genes Chromosomes Cancer
Pays: United States
ID NLM: 9007329

Informations de publication

Date de publication:
12 2022
Historique:
revised: 27 07 2022
received: 25 05 2022
accepted: 07 08 2022
pubmed: 12 8 2022
medline: 12 10 2022
entrez: 11 8 2022
Statut: ppublish

Résumé

Most available molecular data on pancreatic acinar cell carcinoma (PACC) are provided by studies of adult cases. BRAF, RAF1, or RET rearrangements have been described in approximately 30% of cases. To the best of our knowledge, only seven cases with molecular data have been reported in pediatric PACC. We report here the comprehensive study of a pancreatic-type ACC from a 6-year-old patient. We detected an AGAP3::BRAF fusion. This result showing a BRAF rearrangement demonstrates a molecular link between adult and pediatric PACC. Moreover, it identifies AGAP3, a gene located at 7q36.1 that encodes a major component of the N-methyl-d-aspartate (NMDA) receptor signaling complex, as a partner gene of BRAF. The variability of BRAF partners is consistent with a driver role of BRAF alterations in PACC. The identification of such alterations is noteworthy for considering the use of MEK inhibitors in metastatic cases. We did not detect associated genomic instability. The better outcome of pediatric cases might be related to their stable genomic background.

Identifiants

pubmed: 35949061
doi: 10.1002/gcc.23091
pmc: PMC9804258
doi:

Substances chimiques

N-Methylaspartate 6384-92-5
BRAF protein, human EC 2.7.11.1
Proto-Oncogene Proteins B-raf EC 2.7.11.1
Mitogen-Activated Protein Kinase Kinases EC 2.7.12.2

Types de publication

Case Reports Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

734-739

Informations de copyright

© 2022 The Authors. Genes, Chromosomes and Cancer published by Wiley Periodicals LLC.

Références

Genes Chromosomes Cancer. 2022 Dec;61(12):734-739
pubmed: 35949061
Mol Cancer Res. 2020 Apr;18(4):537-548
pubmed: 31911540
Virchows Arch. 2014 Dec;465(6):661-72
pubmed: 25298229
Pathology. 2018 Apr;50(3):345-348
pubmed: 29506751
J Neurosci. 2013 Jul 31;33(31):12586-98
pubmed: 23904596
Front Med (Lausanne). 2015 Jun 15;2:41
pubmed: 26137463
Cell Rep. 2019 Oct 15;29(3):573-588.e7
pubmed: 31618628
Int J Cancer. 2016 Feb 15;138(4):881-90
pubmed: 26314551
Semin Diagn Pathol. 2016 Sep;33(5):307-18
pubmed: 27320062
Mod Pathol. 2020 Apr;33(4):657-664
pubmed: 31558784
Anticancer Res. 2019 Jan;39(1):99-106
pubmed: 30591445
Cancer Discov. 2014 Dec;4(12):1398-405
pubmed: 25266736
Mod Pathol. 2020 Sep;33(9):1811-1821
pubmed: 32358589
Clin Cancer Res. 2017 Sep 15;23(18):5631-5638
pubmed: 28539463
Mod Pathol. 2018 Jan;31(1):132-140
pubmed: 28884748
Virchows Arch. 2009 Feb;454(2):133-42
pubmed: 19066953
Oncologist. 2021 Jan;26(1):e153-e163
pubmed: 32918774
Am J Pathol. 2002 Mar;160(3):953-62
pubmed: 11891193
Virchows Arch. 2018 Oct;473(4):435-441
pubmed: 29721608
Genes Chromosomes Cancer. 2021 Dec;60(12):789-795
pubmed: 34398495
Cancer Discov. 2019 Mar;9(3):329-341
pubmed: 30770389
Nat Commun. 2017 Nov 6;8(1):1323
pubmed: 29109526
JCO Precis Oncol. 2021 Sep 16;5:
pubmed: 34568720
JCO Precis Oncol. 2020 Nov;4:801-805
pubmed: 35050754
Cold Spring Harb Mol Case Stud. 2020 Aug 25;6(4):
pubmed: 32843432
Clin Lung Cancer. 2021 Nov;22(6):e878-e880
pubmed: 34148767

Auteurs

Charlotte Paoli (C)

Central Laboratory of Pathology, Department of Pathology and Molecular Oncology, University Hospital of Nice-Côte d'Azur University, Nice, France.

Fanny Burel-Vandenbos (F)

Central Laboratory of Pathology, Department of Pathology and Molecular Oncology, University Hospital of Nice-Côte d'Azur University, Nice, France.

Aurore Coulomb-l'Hermine (A)

Department of Pathology, Armand Trousseau Hospital, APHP, Paris, France.

Jérôme Cros (J)

Department of Pathology, Beaujon Hospital, Clichy, France.

Morgane Pondrom (M)

Department of Pediatric Oncology and Hematology, University Hospital of Nice-Côte d'Azur University, Nice, France.

Valérie Kubiniek (V)

Laboratory of Solid Tumor Genetics, Department of Pathology and Molecular Oncology, University Hospital of Nice-Côte d'Azur University, Nice, France.
Laboratory of Solid Tumor Genetics, Institute for Research on Cancer and Aging of Nice (IRCAN), Nice, France.

Florence Pedeutour (F)

Laboratory of Solid Tumor Genetics, Department of Pathology and Molecular Oncology, University Hospital of Nice-Côte d'Azur University, Nice, France.
Laboratory of Solid Tumor Genetics, Institute for Research on Cancer and Aging of Nice (IRCAN), Nice, France.

Bérengère Dadone-Montaudié (B)

Central Laboratory of Pathology, Department of Pathology and Molecular Oncology, University Hospital of Nice-Côte d'Azur University, Nice, France.
Laboratory of Solid Tumor Genetics, Department of Pathology and Molecular Oncology, University Hospital of Nice-Côte d'Azur University, Nice, France.
Laboratory of Solid Tumor Genetics, Institute for Research on Cancer and Aging of Nice (IRCAN), Nice, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH